GENETIC IRON OVERLOAD disorders are prevalent yet poorly understood. Over the past 3 years, the discoveries of the hereditary hemochromatosis gene and an intestinal iron transporter have significantly advanced our understanding of iron metabolism. Furthermore, they have suggested novel links between molecules involved in immune defense and iron homeostasis. These findings lay the foundation for developing novel strategies for understanding, diagnosing, and treating patients afflicted with iron overload disorders.

All mammalian cells have an absolute requirement for iron, most likely because iron is abundant, comprising 5% of the earth’s crust, and versatile, existing in two interconvertible redox states. Our Paleolithic ancestors enjoyed a rich meat diet, high in readily absorbable heme iron. Iron deficiency would have been a rare disorder for early humans.1 However, dietary iron deficiency likely became prevalent with the development of agriculture and the consequent decrease in intake of animal products over the past 10,000 years. Hereditary hemochromatosis (HHC), a disorder characterized by inappropriately high intestinal iron absorption, may have conferred a selective advantage in an era when dietary iron was relatively scarce.2 Twentieth century industrialization has been accompanied by a return to increased meat consumption1 and an increase in life expectancy. Under these circumstances, iron loading is no longer an advantage, and HHC has become a prominent disease.

Most iron in mammals exists either as heme, present in heme proteins, or as ferritin, a mobilizable storage form. Only a small fraction enters and leaves the body on a daily basis. Most iron is recycled from the breakdown of effete red blood cells by macrophages of the reticuloendothelial system (RES). At any given time, approximately 0.1% (3 mg) of total body iron circulates in an exchangeable plasma pool. In normal individuals, essentially all circulating plasma iron is bound to transferrin (Tf). The mechanism(s) by which Tf acquires iron from intestinal absorptive cells and RES cells is unknown. Tf is a powerful chelator, binding iron with a dissociation constant of 1022 mol/L−1.3 This chelation serves three purposes: it renders iron soluble under physiologic conditions, it prevents iron-mediated free radical toxicity, and it facilitates transport into cells. Radioactive tracer studies indicate that at least 80% of the iron bound to circulating Tf is delivered to the bone marrow.4 However, when the iron binding capacity of plasma Tf is saturated, as in patients with HHC, the excess non-Tf bound iron is rapidly taken up by hepatocytes and other cells.

Iron is taken into erythroid cells by receptor-mediated endocytosis of Tf (reviewed in Harford et al5). Specific receptors (TfRs) on the outer face of the plasma membrane bind diferric-Tf with high affinity. Once internalized, endosomes are acidified to pH 5.5 to 6.0 through the action of an ATP-dependent proton pump.6-9Endosomal acidification weakens binding of iron to Tf and produces conformational changes in both Tf and TfR, strengthening their association.10,11 Iron release may also be facilitated by a plasma membrane oxidoreductase.12 13 The apo-Tf-TfR complex is recycled back to the plasma membrane, where apo-Tf is discharged, thereby completing an elegant and efficient cycle. Previously, it was not clear how iron exited from the transferrin cycle endosome. However, recent results have given new insights into this process and demonstrated a surprising link between the Tf cycle and intestinal iron absorption (see below).

Iron homeostasis is regulated strictly at the level of intestinal absorption. In normal individuals, intestinal iron absorption is influenced by body iron stores, hypoxia, and erythropoietic activity. The signals regulating absorption remain obscure. Oxidation state, intraluminal pH, and ancillary nutrients such as ascorbic acid can affect the efficiency of uptake. Ferrous iron is most efficiently absorbed. A ferric reductase present on duodenal microvillus membranes may promote absorption by converting dietary ferric iron to the ferrous form.14,15 The intestinal iron transport system also transports cobalt and manganese, the transition metals that flank iron in the periodic table.16 17 

Since the late 1800s, the clinical triad of skin hyperpigmentation, hepatic cirrhosis, and adult onset diabetes has been recognized as evidence of iron overload. It is now clear that HHC is the most prevalent genetic disease in individuals of northern European descent. Patients with this disorder chronically absorb a small excess of iron, and middle-aged homozygotes frequently have 10 times normal body iron stores. As iron stores exceed the body’s capacity for effective chelation, free iron accumulates. Unbound iron is highly toxic, owing to its participation in the generation of free radicals and reactive oxygen intermediates. These molecules provoke peroxidation of membrane lipids leading to cellular injury, ultimately resulting in severe damage to the liver, heart, joints, and endocrine organs. Liver damage may be exacerbated by alcohol consumption or viral hepatitis. The onset of the disease is insidious, and the initial manifestations are often nonspecific symptoms, including fatigue and arthropathy. If untreated, hemochromatosis invariably progresses and is ultimately fatal. However, if diagnosed before end stage organ damage, phlebotomy is an effective and life-saving treatment. Red blood cells are removed at regular intervals to deplete iron stores, and bone marrow erythropoiesis compensates effectively.

The cloning of the causative gene in HHC represents a true tour de force of modern molecular biology. In the mid-1980s the fortuitous discovery of an increased frequency of the HLA-A3 allele in hemochromatosis patients quickly allowed investigators to demonstrate linkage between the phenotype and the HLA complex on human chromosome 6p.18 However, despite this lucky start, nearly 12 years elapsed before the gene was found. Premier human genetics labs around the world devoted years to the effort, but were foiled by severe linkage disequilibrium in the candidate genomic region. Finally, using a novel approach, a small biotech company, Mercator Genetics (now called Progenitor, Menlo Park, CA), found a compelling candidate gene.19 

On the basis of the HLA-A3 association, the Mercator group assumed a strong “founder effect” in hemochromatosis. They postulated that a unique mutation had occurred in the remote past in one ancestor common to most (but not all) affected patients. On the basis of this assumption, they analyzed polymorphic genetic markers throughout a large candidate region to determine which alleles were most frequently present in hemochromatosis patients. Assuming that the original mutation arose on a single chromosome from a single individual, it should be associated with a particular set of alleles of nearby polymorphic markers. They took advantage of the fact that alleles of markers close to the gene were more likely to have been maintained in modern hemochromatosis patients, whereas alleles of more remote markers would have changed through historical recombination events. They performed this analysis looking first at the frequency of occurrence of polymorphic alleles of each marker. Only later did they examine the pattern of alleles in each individual (haplotype), using the haplotype analysis as a means of deducing historic recombination events. This strategy allowed a more precise localization of the causative gene than had previously been possible using linkage studies alone, because information could be assimilated from a large number of individuals who were not known to be related to each other. After narrowing the candidate interval to 250 kb, the Mercator group performed an exhaustive screen for genes within the region, using cDNA selection, exon trapping, and direct genomic sequencing. A single gene emerged as the only plausible candidate for the disease gene. It encodes a protein, HFE (originally called HLA-H), that resembles atypical HLA class I molecules, consistent with the localization of the gene near the HLA cluster.19 This explained an earlier finding that mice lacking β2-microglobulin, a protein associated with HLA class I molecules, developed iron overload resembling that of patients with hemochromatosis.20,21 However, how an atypical class I-like molecule could affect iron homeostasis remained a mystery. Recently, targeted disruption of the HFE gene has provided confirmation of the identity of this gene as the HHC locus and proved that HHC results from a loss of protein function. Zhou et al22 found that HFE knockout mice develop iron overload with features similar to human HHC patients.

Two point mutations have been found within HFE in hemochromatosis patients, but only one of these (Cys282Tyr) has been definitively associated with hemochromatosis and corresponds to the founder mutation.19,23-25 It is thought to have arisen in a single individual, approximately 60 to 70 generations in the past.26 It is most prevalent in individuals of western European descent and rare in individuals of African descent. The discovery of the Cys282Tyr mutation in HFE has had enormous impact on the diagnosis of hemochromatosis, offering a simple polymerase chain reaction (PCR)-based genotyping assay that will identify most (but not all) patients unambiguously. This will complement the use of iron saturation measurements and supplant HLA typing in the majority of HHC patients and allow identification of young homozygotes and heterozygous carriers without biochemical evidence of iron overload. However, it is still important to consider the entire clinical context as a significant proportion of hemochromatosis patients lack the Cys282Tyr mutation, and individuals have been reported who are homozygous for Cys282Tyr but do not show clinical evidence of hemochromatosis.27 

A second HFE polymorphism, His63Asp, has been found in more diverse ethnic backgrounds and may represent an older mutation.28Its clinical significance is less clear, and there are conflicting data as to whether it contributes to iron overload in Cys282Tyr/His63Asp compound heterozygotes (reviewed in Cuthbert29).

The functional role of HFE in iron metabolism remains obscure, but several recent clues have emerged. The crystal structure of normal HFE protein strongly resembles that of class I MHC molecules. Similar to class I molecules, HFE interacts with β2-microglobulin through a domain termed α3 that resembles an Ig constant-like domain.30 However, in contrast to true class I proteins, HFE is not capable of binding short peptides, because the portion of the protein similar to the peptide binding groove in class I molecules has been narrowed. Studies in cells transfected with HFE expression constructs have shown that the Cys282Tyr mutation interferes with binding of β2-microglobulin and consequently prevents normal membrane localization of HFE.31 32 This suggests that normal HFE attenuates iron absorption through some activity on the cell surface.

Three recent studies have reported evidence of a physical interaction between HFE and TfR. TfR was initially found to colocalize with HFE protein by immunohistochemical analysis of human placental syncytiotrophoblasts and to associate with the HFE/β2-microglobulin complex.33 This was confirmed by a more complete biochemical analysis that indicated that normal HFE protein bound to TfR and decreased its affinity for diferric transferrin, whereas Cys282Tyr HFE did not bind to TfR.34 Interestingly, the His63Asp mutant form of HFE also bound to TfR, but did not decrease its affinity for transferrin. This is the first functional evidence that the His63Asp mutation is physiologically significant. Finally, HFE protein covalently linked to a biosensor chip has a high measured affinity for binding TfR at pH 7.5, similar to the pH of the cell surface, but not at pH 6.0, which is similar to the pH within transferrin cycle endosomes.30 A complex forms with a stoichiometry of one TfR homodimer per HFE molecule. The stoichiometry of transferrin in the quarternary complex has not yet been determined. Figure 1 summarizes our current understanding of HFE/TfR interactions.

Fig. 1.

The TfR-HFE complex. The structure of the ternary complex formed by transferrin, TfR, and HFE has not yet been elucidated fully. This cartoon represents our current understanding. (A) Wild-type HFE protein, associated with β2-microglobulin, binds to TfR with high affinity and decreases binding of diferric transferrin.34(B) C282Y HFE protein does not associate with β2-microglobulin and therefore is not expressed in mature form on the cell surface, leaving TfR free to bind transferrin. (C) H63D HFE protein is expressed on the cell surface, but it does not decrease TfR affinity for transferrin to the same extent as wild-type HFE does.

Fig. 1.

The TfR-HFE complex. The structure of the ternary complex formed by transferrin, TfR, and HFE has not yet been elucidated fully. This cartoon represents our current understanding. (A) Wild-type HFE protein, associated with β2-microglobulin, binds to TfR with high affinity and decreases binding of diferric transferrin.34(B) C282Y HFE protein does not associate with β2-microglobulin and therefore is not expressed in mature form on the cell surface, leaving TfR free to bind transferrin. (C) H63D HFE protein is expressed on the cell surface, but it does not decrease TfR affinity for transferrin to the same extent as wild-type HFE does.

Close modal

Despite this progress, it is still not known how HFE regulates iron transport. It is unlikely that HFE acts as an iron transporter directly. It was formerly believed that dietary iron entered the intestinal cell through the transferrin cycle. This hypothesis has been disproved experimentally. The transferrin gene is not expressed in intestinal cells, and transferrin found in the lumen is derived from plasma.35 It is unlikely that plasma transferrin entering bile performs a chelating function in the intestinal lumen, because it is fully saturated with iron before it leaves the biliary system.36 Furthermore, hypoxia, which greatly increases iron absorption, has no effect on intestinal transferrin levels.37 Experiments indicate that endogenous transferrin cannot donate iron to intestinal mucosal cells, and TfRs have been found on basolateral surface, rather than at the brush border membrane.38 39 

However, it is possible that TfR is involved in the transfer of iron across the basolateral (serosal) surface of the absorptive, epithelial enterocyte. Intestinal cells show regulated expression of basolateral TfR that increases in iron deficiency and decreases in iron overload.40 However, surface TfR activity is most prominent in crypt cells and decreases with differentiation of the absorptive epithelium. More differentiated cells demonstrate a redistribution of TfRs from the surface to intracellular sites.41 This makes it unlikely that the TfR is directly responsible for basolateral iron transfer.41 At least two interpretations remain that are not mutually exclusive. It is possible that TfRs are important for supplying iron to rapidly developing enterocyte precursors in the crypts. Alternatively, they may serve to transduce some sort of signal from the body to the future absorptive cells to communicate the need for iron absorption. This latter interpretation is particularly interesting in light of the recently discovered interaction of HFE and TfRs.

Several lines of evidence indicate that patients with HHC have increased iron transfer at the basolateral surface of the absorptive cell.42-44 A larger portion of a oral radiolabeled iron dose is retained in HHC patients than in normal individuals. This indicates that iron taken up by the enterocytes is efficiently transferred to the plasma and not held within the enterocytes as ferritin, to be lost through mucosal sloughing. These findings suggest that mutations in HFE somehow promote basolateral iron export, perhaps because of a failure to interact with the TfR.

However, it remains to be shown that normal HFE interacts with TfR in intestinal cells. The HFE/TfR interaction has been demonstrated in the placenta and in transfected cells; in both cases, TfR was expressed at very high levels. Furthermore, normal HFE protein was detected in an intracellular, paranuclear compartment in small intestine cells, and it was exclusively found in the crypts.45 Although it is intriguing to postulate that HFE interacts with TfR in intestinal cells in a regulatory fashion, presumably to transduce information from circulating mediators as to the state of body iron stores, it is not clear that HFE and TfR are present in the same subcellular location.

Another big piece in the iron overload puzzle came 1 year after HFE was discovered, when two groups, using two quite different approaches, simultaneously reported the identification of an intestinal iron transporter. Both used iron-deficient rodents as experimental models.

Microcytic anemia mice (gene symbol mk) have an autosomal recessive defect in iron metabolism that includes marked impairment of intestinal iron transport.46-48 They have no abnormalities in Tf, TfR, ferritin, or the RNA binding iron regulatory proteins. The phenotype suggested that the causative mutation was likely to be in an intestinal transporter functioning at the brush border.48-50 Using a positional cloning strategy, Fleming et al51 localized the mk mutation to theNramp2 gene on mouse chromosome 15 and found a glycine to arginine (Gly185Arg) missense mutation unique to animals with themk phenotype. Nramp2 had been an orphan protein with no known function cloned based on its homology to Nramp1, a molecule involved in macrophage host defense.52 53 

In parallel experiments, Gunshin et al54 searched for an intestinal iron transporter using a Xenopus oocyte expression cloning system and found a single cDNA that stimulated iron transport. This cDNA encoded rat Nramp2 (referred to as DCT-1 in their report). They went on to show that Nramp2(DCT1) transported a variety of other heavy metals as well, including cobalt, manganese, lead, zinc, and copper, and that protons were cotransported. These data concurred with earlier physiology studies that indicated that the human intestinal iron transporter also transports other metals.16,17 55 Iron-deficient rats showed a dramatic increase in the amount of Nramp2(DCT1) mRNA in small intestine enterocytes, consistent with a role for Nramp2(DCT1) as a major iron transport protein. Taken together, the genetic and biochemical characterizations of Nramp2(DCT1) make a compelling argument that it is the primary intestinal transporter involved in apical iron uptake.

Mammalian cells transfected with Nramp2 cDNA expression constructs have markedly increased iron uptake as compared with control transfectants. Transfection of Nramp2 cDNA carrying themk mutation confers minimal iron uptake capability, indicating that the Gly185Arg mutation is highly deleterious to Nramp2(DCT1) function.56 Surprisingly, a second mutant animal with autosomal recessive iron deficiency, the Belgrade rat (gene symbolb), also carries a mutation in Nramp2(DCT1).57 Homozygous mutant b rats have a well-characterized defect in the transferrin cycle in erythroid cells, as well as defective intestinal iron transport.58-64 Their phenotype resembles that of mk mice in having defects at both levels, but the intestinal abnormality was better studied in mkanimals, and the erythroid abnormality was better understood inb animals. The identification of a mutation within the b Nramp2 gene confirms that Nramp2(DCT1) is not only important in intestinal iron absorption, but also for erythroid use (Fig 2). Nramp2(DCT1) functions in export of iron from Tf cycle endosomes. Remarkably, the b mutation results in exactly the same amino acid change (Gly185Arg) as themk mutation. This alteration in Nramp2(DCT1) protein seems to be the unique cause of the mk-like phenotype in rodents.

Fig. 2.

Critical steps in mammalian iron transport. Key iron transport steps are diagrammed, showing the route dietary iron follows from the intestinal lumen to the cytoplasm of an erythroid precursor cell. Nramp2(DCT1) acts as an iron transporter at two steps. It is required for transfer of iron across the intestinal brush border and for export of iron from transferrin cycle endosomes in the bone marrow. The function of Hfe is not well understood, but it appears to regulate basolateral iron transfer from enterocyte to plasma. Transferrin (Tf) chelates circulating iron in plasma.

Fig. 2.

Critical steps in mammalian iron transport. Key iron transport steps are diagrammed, showing the route dietary iron follows from the intestinal lumen to the cytoplasm of an erythroid precursor cell. Nramp2(DCT1) acts as an iron transporter at two steps. It is required for transfer of iron across the intestinal brush border and for export of iron from transferrin cycle endosomes in the bone marrow. The function of Hfe is not well understood, but it appears to regulate basolateral iron transfer from enterocyte to plasma. Transferrin (Tf) chelates circulating iron in plasma.

Close modal

The mk and b phenotypes are severe, suggesting that Nramp2(DCT1) function is essential for normal intestinal iron transport, at least in mice and rats. It has not yet been determined whether Nramp2(DCT1) expression or activity is altered in patients with HHC. There is compelling evidence that Nramp2(DCT1) acts as the apical transporter that brings iron into enterocytes, and HHC seems to affect basolateral iron transport (Fig 2). However, it is possible that HHC patients have increased Nramp2(DCT1) function consequent to more rapid export of iron from enterocytes or as a result of an altered regulatory mechanism. This will need to be investigated. However, whether or not HHC alters Nramp2(DCT1) function, the mk and b animal models suggests that Nramp2(DCT1) would be an ideal target for pharmacological blockade of iron absorption. It may be possible to develop drugs that could be administered orally to specifically block Nramp2(DCT1) function in patients with iron overload disorders. At present, hemochromatosis patients must undergo phlebotomy every few weeks to maintain a slightly iron-deficient state. Perhaps an oral, nonabsorbable agent might be developed that could inhibit Nramp2(DCT1) without systemic side effects. Such a drug could offer a significant improvement in the quality of life for patients with hemochromatosis. It might also find uses in treating siderosis associated with thalassemia and other metal intoxication disorders such as lead poisoning.

Although great strides have been made towards understanding iron transport and associated disorders, many questions remain. Despite intensive investigation and its tantalizing association with the TfR, it is still unclear how HFE functions in normal individuals. To date, only two functionally significant mutations in HFE have been discovered; is it possible that additional mutations will be found that contribute to iron overload or iron deficiency disorders? What is the etiology of iron overload in patients without Cys282Tyr mutations?

Nramp2(DCT1) is not only expressed in intestinal cells; it is expressed in most if not all tissues and seems to be particularly actively expressed in certain brain structures.54 What role does it play in iron uptake in the central nervous system? Does its function contribute to the pathology associated with increased metal deposition in patients with Parkinson’s disease, Alzheimer’s disease, and other conditions?65 Are there human patients with mutations in Nramp2(DCT1)?

It now seems likely that the role of Nramp1 in host defense also involves movement of metal ions. Nramp1 is expressed exclusively in macrophages and is localized to phagolysosomes.53,66 Normal Nramp1 causes an attenuation of replication of a variety of ferrophilic intracellular pathogens, including several Mycobacteriaspecies, Leishmania, and Salmonella typhimurium. A point mutation in Nramp1 leads to rampant pathogen proliferation, but no alteration of normal host killing mechanisms.53 Nramp1 carrying this mutation is undetectable in macrophages.66 These observations strongly suggest that Nramp1 may act by removing a necessary metal, presumably iron, from the intracellular compartment containing the invaders, thus starving them of an essential nutrient.

What function does Nramp1 serve in normal, uninfected cells? Intriguingly, it is expressed exclusively in reticuloendothelial macrophages. These cells play a fundamental role in iron metabolism, by phagocytosing effete red blood cells, breaking down their hemoglobin, and recycling iron to transferrin for delivery back to the erythron.67 The bulk of iron used for erythropoiesis has passed through this recycling pathway. Perhaps Nramp1 plays a special role in this process. Accordingly, it has been established that various inflammatory cytokines that are associated with anemia of chronic disease68 also affect the regulation of Nramp1.69 One might speculate that the failure of normal iron recycling in anemia of chronic disease might be a consequence of alterations in the expression or activity of Nramp1. This needs to be investigated.

Nramp2(DCT1) is abundantly expressed in the proximal tubules and collecting ducts of the kidney, suggesting that it might be involved in metal reabsorption.54 This raises the intriguing possibility that there may be a potential excretory system for iron after all and that it is overcome by constitutive reabsorption. If so, it is conceivable that reabsorption could be blocked pharmacologically, resulting in a urinary iron leak. This type of therapeutic maneuver could be invaluable in dealing with patients with siderosis due to a chronic transfusion requirement, for example, in patients with myelodysplastic syndromes or thalassemia major.

The severe mk and b phenotypes indicate that Nramp2(DCT1) is a key transmembrane iron transporter, at least in intestinal cells and erythroid cells. Nramp2(DCT1) may be involved in iron transport in other cell types as well. Nonetheless, there is indisputable biochemical evidence for multiple iron transport activities in mammalian cells, and there are clearly several iron transporters operating in yeast. Database searches to date have not shown additional mammalian Nramp-like proteins; it appears likely that other mammalian iron transport molecules will be unrelated. One candidate molecule, SFT (stimulator of Fe transport), was recently isolated in an expression cloning screen using K562 erythroleukemia cell mRNA.70 This molecule appears to promote iron uptake, but there is no direct evidence that it is, itself, an iron transporter. A high-affinity transmembrane iron transporter found in yeast, FTR1, is clearly important for iron homeostasis in that organism, but it has no known mammalian homolog at this time.71 

Finally, there are two other iron overload disorders, not yet mentioned in this review, that are still poorly understood. African iron overload, also known as Bantu siderosis, is a prevalent condition in sub-Saharan Africa that leads to massive iron accumulation and ensuing complications.72 The phenotype of African iron overload differs subtly from that of HHC on a pathologic level, as iron first accumulates in reticuloendothelial cells. Furthermore, though there is a genetic predisposition, African iron overload is not linked to the HLA complex.73 It is not yet known whether African-Americans have an increased susceptibility to iron overload as a result of this same gene. A different disorder, neonatal hemochromatosis, is a devastating iron loading disease of the perinatal period that results in liver failure and almost certain death in affected patients. Liver transplant is apparently futile, because iron has been shown to accumulate in the donor organ.74 Future efforts must be directed towards working out the pathogenesis of these diseases and using our new knowledge in their treatment.

The authors thank Mark Fleming for stimulating discussions and for help in preparing Fig 2.

N.C.A. is an Assistant Investigator of the Howard Hughes Medical Institute. J.E.L. is supported by a National Institutes of Health (NIH) K08 award. Some studies described in this review are funded by NIH R01 DK53813 to N.C.A.

Address reprint requests to Nancy C. Andrews, MD, PhD, Howard Hughes Medical Institute, Enders 720, Children’s Hospital, 300 Longwood Ave, Boston, MA 02115; e-mail: andrews_n@a1.tch.harvard.edu.

1
Eaton
SB
Konner
M
Paleolithic nutrition: A consideration of its nature and current implications.
N Engl J Med
312
1985
283
2
Barton
JC
Bertoli
LF
Hemochromatosis: The genetic disorder of the twenty-first century.
Nat Med
2
1996
394
3
Aisen
P
Listowsky
I
Iron transport and storage proteins.
Annu Rev Biochem
49
1980
357
4
Finch
CA
Huebers
H
Perspectives in iron metabolism.
N Engl J Med
306
1982
1520
5
Klausner
RD
Molecular mechanisms of iron metabolism
Stamatoyannopoulos
G
Nienhuis
AW
Majerus
PW
Varmus
H
The Molecular Basis of Blood Diseases.
1994
351
Saunders
Philadelphia, PA
6
Dautry-Varsat
A
Ciechanover
A
Lodish
HF
pH and the recycling of transferrin during receptor-mediated endocytosis.
Proc Natl Acad Sci USA
80
1983
2258
7
Paterson
S
Armstrong
NJ
Iacopetta
BJ
McArdle
HJ
Morgan
EH
Intravesicular pH and iron uptake by immature erythroid cells.
J Cell Physiol
120
1984
225
8
Van Renswoude
J
Bridges
KR
Harford
JB
Klausner
RD
Receptor-mediated endocytosis and the uptake of iron in K562 cells: Identification of a non-lysosomal acidic compartment.
Proc Natl Acad Sci USA
79
1982
6186
9
Yamashiro
DJ
Tycko
B
Fluss
SR
Maxfield
FR
Segregation of transferrin to a mildly acidic (pH 6.5) para-Golgi compartment in the recycling pathway.
Cell
37
1984
789
10
Bali
PK
Zak
O
Aisen
P
A new role for the transferrin receptor in the release of iron from transferrin.
Biochemistry
30
1991
324
11
Sipe
DM
Murphy
RF
Binding to cellular receptors results in increased iron release from transferrin at mildly acidic pH.
J Biol Chem
266
1991
8002
12
Nunez
M-T
Gaete
V
Watkins
JA
Glass
J
Mobilization of iron from endocytic vesicles. The effects of acidification and reduction.
J Biol Chem
265
1990
6688
13
Thorstensen
K
Romslo
I
Uptake of iron from transferrin by isolated rat hepatocytes. A redox-mediated plasma membrane process?
J Biol Chem
263
1988
8844
14
Reidel
H-D
Remus
AJ
Fitscher
BA
Stremmel
W
Characterization and partial purification of a ferrireductase from human duodenal microvillus membranes.
Biochem J
309
1995
745
15
Ekmekcioglu
C
Feyertag
J
Marktl
W
A ferric reductase activity is found in brush border membrane vesicles isolated from Caco-2 cells.
J Nutr
126
1996
2209
16
Thomson
ABR
Olatunbosun
D
Valberg
LS
Interrelation of intestinal transport system for manganese and iron.
J Lab Clin Med
78
1971
642
17
Schade
SG
Felsher
BF
Glader
BE
Conrad
ME
Effect of cobalt on iron absorption.
Proc Soc Exp Biol Med
134
1970
741
18
Simon
M
Bourel
M
Fauchet
R
Genetet
B
Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis.
Gut
17
1976
332
19
Feder
JN
Gnirke
A
Thomas
W
Tsuchihashi
Z
Ruddy
DA
Basava
A
Dormishian
F
Domingo
R
Ellis
MC
Fullan
A
Hinton
LM
Jones
NL
Kimmel
BE
Kronmal
GS
Lauer
P
Lee
VK
Loeb
DB
Mapa
FA
McClelland
E
Meyer
NC
Mintier
GA
Moeller
N
Moore
T
Morikang
E
Prass
CE
Quintana
L
Starnes
SM
Schatzman
RC
Brunke
KJ
Drayna
DT
Risch
NJ
Bacon
BR
Wolff
RK
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.
Nat Genet
13
1996
399
20
de Sousa
M
Reimao
R
Lacerda
R
Hugo
P
Kaufmann
SHE
Porto
G
Iron overload in beta2-microglobulin deficient mice.
Immunol Lett
39
1994
105
21
Rothenberg
BE
Voland
JR
Beta 2 knockout mice deveop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism.
Proc Natl Acad Sci USA
93
1996
1529
22
Zhou
XY
Tomatsu
S
Fleming
RE
Parkkila
S
Waheed
A
Jiang
J
Fei
Y
Brunt
EM
Ruddy
DA
Prass
CE
Schatzman
RC
O’Neill
R
Britton
RS
Bacon
BR
Sly
WS
HFE gene knockout produces mouse model of hereditary hemochromatosis.
Proc Natl Acad Sci USA
95
1998
2492
23
Jazwinska
EC
Cullen
LM
Busfield
F
Pyper
WR
Webb
SI
Powell
LW
Morris
CP
Walsh
TP
Haemochromatosis and HLA-H.
Nat Genet
14
1996
249
24
Jouanolle
AM
Gandon
G
Jezequel
P
Blayau
M
Campion
ML
Yaouanq
J
Mosser
J
Fergelot
P
Chauvel
B
Bouric
P
Carn
G
Andrieux
N
Gicquel
I
Le Gall
JY
David
V
Haemochromatosis and HLA-H.
Nat Genet
14
1996
251
25
Beutler
E
Gelbart
T
West
C
Lee
P
Adams
M
Blackstone
R
Pockros
P
Kosty
M
Venditti
CP
Phatak
PD
Seese
NK
Chorney
KA
Ten Elshof
AE
Gerhard
GS
Chorney
M
Mutation analysis in hereditary hemochromatosis.
Blood Cells Mol Dis
22
1996
187
26
Ajioka
RS
Jorde
LB
Gruen
JR
Dimitrova
D
Barrow
J
Radisky
E
Edwards
CQ
Griffen
LM
Kushner
JP
Haplotype analysis of hemochromatosis: Evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes.
Am J Hum Genet
60
1997
1439
27
Adams
PC
Chakrabarti
S
Genotypic/phenotypic correlations in genetic hemochromatosis: Evolution of diagnostic criteria.
Gastroenterology
114
1998
319
28
Roth
MP
Giraldo
P
Hariti
G
Poloni
ES
Sanchezmazas
A
Destefano
GF
Dugoujon
JM
Coppin
H
Absence of the hemochromatosis gene Cys282Tyr mutation in three ethnic groups from Algeria (MZAB), Ethiopia and Senegal.
Immunogenetics
46
1997
222
29
Cuthbert
JA
Iron, HFE and hemochromatosis update.
J Invest Med
45
1997
518
30
Lebron
JA
Bennett
MJ
Vaughn
DE
Chirino
AJ
Snow
PM
Mintier
GA
Feder
JN
Bjorkman
PJ
Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor.
Cell
93
1998
111
31
Waheed
A
Parkkila
S
Zhou
XY
Tomatsu
S
Tsuchihashi
Z
Feder
JN
Schatzman
RC
Britton
RS
Bacon
BR
Sly
WS
Hereditary hemochromatosis: Effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells.
Proc Natl Acad Sci USA
94
1997
12384
32
Feder
JN
Tsuchihashi
Z
Irrinki
A
Lee
VK
Mapa
FA
Morikang
E
Prass
CE
Starnes
SM
Wolff
RK
Parkkila
S
Sly
WS
Schatzman
RC
The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression.
J Biol Chem
272
1997
14025
33
Parkkila
S
Waheed
A
Britton
RS
Bacon
BR
Zhou
XY
Tomatsu
S
Fleming
RE
Sly
WS
Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis.
Proc Natl Acad Sci USA
94
1997
13198
34
Feder
JN
Penny
DM
Irrinki
A
Lee
VK
Lebron
JA
Watson
N
Tsuchihashi
Z
Sigal
E
Bjorkman
PJ
Schatzman
RC
The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding.
Proc Natl Acad Sci USA
95
1998
1472
35
Idzerda
RL
Huebers
H
Idzerda
RL
Huebers
H
Finch
CA
McKnight
GS
Rat transferrin gene expression: Tissue-specific regulation by iron deficiency.
Proc Natl Acad Sci USA
83
1986
3723
36
Schumann
K
Schafer
SG
Forth
W
Iron absorption and biliary excretion of transferrin in rats.
Res Exp Med
186
1986
215
37
Simpson
RJ
Osterloh
KRS
Raja
KB
Snape
SD
Peters
TJ
Studies on the role of transferrin and endocytosis on the uptake of Fe3+ from Fe-nitriloacetate by mouse duodenum.
Biochim Biophys Acta
884
1986
166
38
Bezwoda
WR
MacPhail
AP
Bothwell
TH
Baynes
RD
Derman
DP
Torrance
JD
Failure of transferrin to enhance iron absorption in achlorhydric human subjects.
Br J Haematol
63
1986
749
39
Parmley
RT
Barton
JC
Conrad
ME
Ultrastructural localization of transferrin, transferrin receptor and iron-binding sites on human placental and duodenal microvilli.
Br J Haematol
60
1985
81
40
Anderson
GJ
Powell
LW
Halliday
JW
Transferrin receptor distribution and regulation in the rat small inestine. Effect of iron stores and erythropoiesis.
Gastroenterology
98
1990
576
41
Anderson
GJ
Walsh
MD
Powell
LW
Halliday
JW
Intestinal transferrin receptors and iron absorption in the neonatal rat.
Br J Haematol
77
1991
229
42
Powell
LW
Campbell
CB
Wilson
E
Intestinal mucosal uptake of iron and iron retention in idiopathic haemochromatosis as evidence for a mucosal abnormality.
Gut
11
1970
727
43
McLaren
GD
Nathanson
MH
Jacobs
A
Trevett
D
Thomson
W
Regulation of intestinal iron absorption and mucosal iron kinetics in hereditary hemochromatosis.
J Lab Clin Med
117
1991
390
44
Pietrangelo
A
Rocchi
E
Casalgrandi
G
Rigo
G
Ferrari
A
Perini
M
Ventura
E
Cairo
G
Regulation of transferrin, transferrin receptor and ferritin genes in human duodenum.
Gastroenterology
102
1992
802
45
Parkkila
S
Waheed
A
Britton
RS
Feder
JN
Tsuchihashi
Z
Schatzman
RC
Bacon
BR
Sly
WS
Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract.
Proc Natl Acad Sci USA
94
1997
2534
46
Russell
ES
Nash
DJ
Bernstein
SE
Kent
EL
McFarland
EC
Matthews
SM
Norwood
MS
Characterization and genetic studies of microcytic anemia in house mouse.
Blood
35
1970
838
47
McFarland
EC
Russell
ES
Microcytic anemia (mk) has been located close to Ca on chromosome 15.
Mouse News Letter
53
1975
35
48
Edwards
JA
Hoke
JE
Defect of intestinal mucosal iron uptake in mice with hereditary microcytic anemia.
Proc Soc Exp Biol Med
141
1972
81
49
Bannerman
RM
Edwards
JA
Kreimer-Birnbaum
M
McFarland
E
Russell
ES
Hereditary microcytic anaemia in the mouse; studies in iron distribution and metabolism.
Br J Haematol
23
1972
235
50
Harrison
DE
Marrow transplantation and iron therapy in mouse hereditary microcytic anemia.
Blood
40
1972
893
51
Fleming
MD
Trenor
CCI
Su
MA
Foernzler
D
Beier
DR
Dietrich
WF
Andrews
NC
Microcytic anemia mice have a mutation in Nramp2, a candidate iron transporter.
Nat Genet
16
1997
383
52
Grunheid
S
Cellier
M
Vidal
S
Gros
P
Identification and characterization of a second mouse Nramp gene.
Genomics
25
1995
514
53
Vidal
SM
Malo
D
Vogan
K
Skamene
E
Gros
P
Natural resistance to infection with intracellular parasites: Isolation of a candidate for Bcg.
Cell
73
1993
469
54
Gunshin
H
Mackenzie
B
Berger
UV
Gunshin
Y
Romero
MF
Boron
WF
Nussberger
S
Gollan
JL
Hediger
MA
Cloning and characterization of a mammalian proton-coupled metal-ion transporter.
Nature
388
1997
482
55
Flanagan
PR
Haist
J
MacKenzie
I
Valberg
LS
Intestinal absorption of zinc: Competitive interactions with iron, cobalt and copper in mice with sex-linked anemia (sla).
Can J Physiol Pharmacol
62
1984
1124
56
Su
MA
Trenor CC
III
Fleming
JC
Fleming
MD
Andrews
NC
The G185R mutation disrupts function of iron transporter Nramp2.
Blood
92
1998
2157
57
Fleming
MD
Romano
MA
Garrick
LM
Garrick
MD
Andrews
NC
Anemia of the Belgrade rat is caused by a mutation in iron transporter protein Nramp2.
Proc Natl Acad Sci USA
95
1998
1148
58
Sladic-Simic
D
Martinovich
PN
Zivkovic
N
Pavic
D
Martinovic
J
Kahn
M
Ranney
HM
A thalassemia-like disorder in Belgrade laboratory rats.
Ann NY Acad Sci
165
1969
93
59
Edwards
JA
Sullivan
AL
Hoke
JE
Defective delivery of iron to the developing red cell of the Belgrade laboratory rat.
Blood
55
1980
645
60
Edwards
J
Huebers
H
Kunzler
C
Finch
C
Iron metabolism in the Belgrade rat.
Blood
67
1986
623
61
Farcich
EA
Morgan
EH
Uptake of transferrin-bound and nontransferrin-bound iron by reticulocytes from the Belgrade laboratory rat: Comparison with Wistar rat transferrin and reticulocytes.
Am J Hematol
39
1992
9
62
Farcich
EA
Morgan
EH
Diminished iron acquisition by cells and tissues of Belgrade laboratory rats.
Am J Physiol
262
1992
R220
63
Garrick
MD
Gniecko
K
Liu
Y
Cohan
DS
Garrick
LM
Transferrin and the transferrin cycle in Belgrade rat reticulocytes.
J Biol Chem
20
1993
14867
64
Garrick
M
Scott
D
Walpole
S
Finkelstein
E
Whitbred
J
Chopra
S
Trivikram
L
Mayes
D
Rhodes
D
Cabbagestalk
K
Oklu
R
Sadiq
A
Mascia
B
Hoke
J
Garrick
L
Iron supplementation moderates but does not cure the Belgrade anemia.
Biometals
10
1997
65
65
Olanow
CW
Arendash
GW
Metals and free radicals in neurodegeneration.
Curr Opin Neurol
7
1994
548
66
Grunheid
S
Pinner
E
Desjardins
M
Gros
P
Natural resistance to infection with intracellular pathogens: The Nramp1 protein is recruited to the membrane of the phagosome.
J Exp Med
185
1997
717
67
Sears
DA
Anemia of chronic disease.
Med Clin North Am
76
1992
567
68
Means
RT
Pathogenesis of the anemia of chronic disease: A cytokine-mediated anemia [Review].
Stem Cells
13
1995
32
69
Govoni
G
Gauthier
S
Billia
F
Iscove
NN
Cell-specific and inducible Nramp1 gene expression in mouse macrophages in vitro and in vivo.
J Leukoc Biol
62
1997
277
70
Gutierrez
JA
Yu
J
Rivera
S
Wessling-Resnick
M
Functional expression cloning and characterization of SFT, a stimulator of Fe transport.
J Cell Biol
139
1997
895
71
Stearman
R
Yuan
DS
Yamaguchi-Iwai
Y
Klausner
RD
Dancis
A
A permease-oxidase complex involved in high-affinity iron uptake in yeast.
Science
271
1996
1552
72
Gordeuk
V
Mukiibi
J
Hasstedt
SJ
Samowitz
W
Edwards
CQ
West
G
Ndambire
S
Emmanual
J
Nkanza
N
Chapanduka
Z
Randall
M
Boone
P
Romano
P
Martell
RW
Yamashita
T
Effler
P
Brittenham
GM
Iron overload in Africa. Interaction between a gene and dietary iron content.
N Engl J Med
326
1992
95
73
Moyo
VM
Gangaidzo
IT
Gomo
ZA
Khumalo
H
Saungweme
T
Kiire
CF
Rouault
T
Gordeuk
VR
Traditional beer consumption and the iron status of spouse pairs from a rural community in Zimbabwe.
Blood
89
1997
2159
74
Egawa
H
Berquist
W
Garcia-Kennedy
R
Cox
K
Knisely
AS
Esquivel
CO
Rapid development of hepatocellular siderosis after liver transplantation for neonatal hemochromatosis.
Transplantation
62
1996
1511
Sign in via your Institution